Rahpeyma Mehdi, Samarbaf-Zadeh Alireza, Makvandi Manoochehr, Ghadiri Ata A, Dowall Stuart D, Fotouhi Fatemeh
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Virology, WHO Collaborating Center for Reference and Research on Rabies, Pasteur Institute of Iran, Pasteur Institute, Tehran, Iran.
Arch Virol. 2017 Jul;162(7):1951-1962. doi: 10.1007/s00705-017-3315-3. Epub 2017 Mar 18.
Crimean-Congo hemorrhagic fever virus (CCHFV) is a major cause of tick-borne viral hemorrhagic disease in the world. Despite of its importance as a deadly pathogen, there is currently no licensed vaccine against CCHF disease. The attachment glycoprotein of CCHFV (Gn) is a potentially important target for protective antiviral immune responses. To characterize the expression of recombinant CCHFV Gn in an insect-cell-based system, we developed a gene expression system expressing the full-length coding sequence under a polyhedron promoter in Sf9 cells using recombinant baculovirus. Recombinant Gn was purified by affinity chromatography, and the immunoreactivity of the protein was evaluated using sera from patients with confirmed CCHF infection. Codon-optimized Gn was successfully expressed, and the product had the expected molecular weight for CCHFV Gn glycoprotein of 37 kDa. In time course studies, the optimum expression of Gn occurred between 36 and 48 hours postinfection. The immunoreactivity of the recombinant protein in Western blot assay against human sera was positive and was similar to the results obtained with the anti-V5 tag antibody. Additionally, mice were subjected to subcutaneous injection with recombinant Gn, and the cellular and humoral immune response was monitored. The results showed that recombinant Gn protein was highly immunogenic and could elicit high titers of antigen-specific antibodies. Induction of the inflammatory cytokine interferon-gamma and the regulatory cytokine IL-10 was also detected. In conclusion, a recombinant baculovirus harboring CCHFV Gn was constructed and expressed in Sf9 host cells for the first time, and it was demonstrated that this approach is a suitable expression system for producing immunogenic CCHFV Gn protein without any biosafety concerns.
克里米亚-刚果出血热病毒(CCHFV)是世界上蜱传病毒性出血热疾病的主要病因。尽管它作为一种致命病原体具有重要性,但目前尚无针对CCHF疾病的许可疫苗。CCHFV的附着糖蛋白(Gn)是保护性抗病毒免疫反应的潜在重要靶点。为了表征重组CCHFV Gn在基于昆虫细胞的系统中的表达,我们开发了一种基因表达系统,使用重组杆状病毒在Sf9细胞的多角体启动子下表达全长编码序列。重组Gn通过亲和层析纯化,并使用确诊CCHF感染患者的血清评估该蛋白的免疫反应性。密码子优化的Gn成功表达,产物具有CCHFV Gn糖蛋白预期的37 kDa分子量。在时间进程研究中,Gn的最佳表达发生在感染后36至48小时之间。重组蛋白在Western印迹分析中对人血清的免疫反应性为阳性,且与抗V5标签抗体获得的结果相似。此外,给小鼠皮下注射重组Gn,并监测细胞和体液免疫反应。结果表明,重组Gn蛋白具有高度免疫原性,可引发高滴度的抗原特异性抗体。还检测到炎性细胞因子干扰素-γ和调节性细胞因子IL-10的诱导。总之,首次构建了携带CCHFV Gn的重组杆状病毒并在Sf9宿主细胞中表达,并且证明该方法是一种适合生产具有免疫原性的CCHFV Gn蛋白且无任何生物安全问题的表达系统。